PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me

Journal of Nuclear Medicine

Volumn 53, Issue 5, 2012, Pages 741-748

  Takashima, Tadayuki ^a,b   Kitamura, Satoshi ^c   Wada, Yasuhiro ^a,b   Tanaka, Masaaki ^b   Shigihara, Yoshihito ^b   Ishii, Hideki ^a,b   Ijuin, Ryosuke ^a,b   Shiomi, Susumu ^b   Nakae, Takahiro ^a   Watanabe, Yumiko ^a   Cui, Yilong ^a   Doi, Hisashi ^a   Suzuki, Masaaki ^a   Maeda, Kazuya ^c   Kusuhara, Hiroyuki ^c   Sugiyama, Yuichi ^c   Watanabe, Yasuyoshi ^a,b  

^a RIKEN   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

(15R) 16 m tolyl 17; 18; 19; 20 tetranorisocarbacyclin methyl ester; Drug drug interaction; Hepatobiliary transport; Organic anion transporting polypeptide; PET

Indexed keywords

16 M TOLYL 17,18,19,20 TETRANORISOCARBACYCLIN METHYL ESTER C 11; DRUG CARRIER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; RIFAMPICIN; TRACER; UNCLASSIFIED DRUG;

ARTICLE; BILE FLOW; BLOOD SAMPLING; DIGESTIVE FUNCTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG HYDROLYSIS; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; HEPATOBILIARY TRANSPORT; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; ISOTOPE LABELING; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOACTIVITY; SINGLE DRUG DOSE; VENOUS BLOOD;

ABDOMEN; ADULT; BICYCLO COMPOUNDS; BILE CANALICULI; BILIARY TRACT; BIOLOGICAL TRANSPORT; CELLS, CULTURED; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; ORGANIC ANION TRANSPORTERS; PENTANOIC ACIDS; POSITRON-EMISSION TOMOGRAPHY; RIFAMPIN; TIME FACTORS;

EID: 84860781184     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.098681     Document Type: Article

References (31)

1. Chiba M, Ishii Y, Sugiyama Y. Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J. 2009;11:262-276.
2. Nies AT, Schwab M, Keppler D. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol. 2008;4:545-568. (Pubitemid 351890738)
3. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol. 2005;45: 689-723. (Pubitemid 40261822)
4. Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet. 2008;23:223-235.
5. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: Implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol. 2009;5:703-729.
6. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81:194-204. (Pubitemid 46174816)
7. Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 2007;453:643-659. (Pubitemid 46192536)
8. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci. 2006;27:425-446. (Pubitemid 43363338)
9. König J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:432-443.
10. Sissung TM, Gardner ER, Gao R, Figg WD. Pharmacogenetics of membrane transporters: A review of current approaches. Methods Mol Biol. 2008;448:41-62.
11. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxelinduced leukopenia. Cancer Sci. 2008;99:967-972. (Pubitemid 351997599)
12. Bergström M, Grahnen A, Langstrom B. Positron emission tomography microdosing: A new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol. 2003;59:357-366. (Pubitemid 37214939)
13. Riemann B, Schafers KP, Schober O, Schafers M. Small animal PET in preclinical studies: Opportunities and challenges. Q J Nucl Med Mol Imaging. 2008;52:215-221.
14. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008;7:591-607. (Pubitemid 351927724)
15. Takashima T, Nagata H, Nakae T, et al. Positron emission tomography studies using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin methyl ester for the evaluation of hepatobiliary transport. J Pharmacol Exp Ther. 2010;335: 314-323.
16. Suzuki M, Doi H, Björkman M, et al. Rapid methylation on carbon frameworks leading to the synthesis of a PET tracer capable of imaging a novel CNS-type prostacyclin receptor in living human brain. Trends Analyt Chem. 2004;23:595-607. (Pubitemid 39232082)
17. Björkman M, Andersson Y, Doi H, et al. Synthesis of 11C/13C-labelled prostacyclins. Acta Chem Scand. 1998;52:635-640.
18. Kim DC, Sugiyama Y, Satoh H, Fuwa T, Iga T, Hanano M. Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J Pharm Sci. 1988;77:200-207.
19. Li N, Bi YA, Duignan DB, Lai Y. Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes. Mol Pharm. 2009;6:1180-1189.
20. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311:139-146. (Pubitemid 39287793)
21. Maeda K, Kambara M, Tian Y, Hofmann AF, Sugiyama Y. Uptake of ursodeoxycholate and its conjugates by human hepatocytes: Role of Na(1)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and OATP1B3 (OATP8). Mol Pharm. 2006;3:70-77. (Pubitemid 43331753)
22. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34: 1229-1236.
23. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008; 36:2014-2023.
24. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn. 1981;4:879-885. (Pubitemid 12174128)
25. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093-1095. (Pubitemid 23211439)
26. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36:164-172. (Pubitemid 34700774)
27. Kohno HHB, Tsuchiya T, Kubo H, Kobayashi Y. Pharmacokinetics of ifampicin. Rinsyo Yakuri. 1982;13:403-412.
28. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003;304:223-228. (Pubitemid 36008932)
29. Nakanishi T, Shibue Y, Fukuyama Y, et al. Quantitative time-lapse imaging (QTLI)-based analysis of drug-drug interaction mediated by hepatobiliary transporter, multidrug associated protein 2, in sandwich-cultured rat hepatocytes. Drug Metab Dispos. 2011;39:984-991.
30. Yoshida K, Maeda K, Sugiyama Y. Prediction of the degree of transportermediated drug-drug interactions involving OATP substrates based on in vitro inhibition studies. Clin Pharmacol Ther. In press.
31. Ghibellini G, Leslie EM, Pollack GM, Brouwer KL. Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: Integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res. 2008;25: 1851-1860.